207 related articles for article (PubMed ID: 9718265)
1. Dopamine D2 receptor agonists protect against ischaemia-induced hippocampal neurodegeneration in global cerebral ischaemia.
O'Neill MJ; Hicks CA; Ward MA; Cardwell GP; Reymann JM; Allain H; Bentué-Ferrer D
Eur J Pharmacol; 1998 Jul; 352(1):37-46. PubMed ID: 9718265
[TBL] [Abstract][Full Text] [Related]
2. [Effects of D1 and D2 dopamine receptor agonists and antagonists on cerebral ischemia/reperfusion injury].
Zong XM; Zeng YM; Xu T; Lü JN
Sheng Li Xue Bao; 2003 Oct; 55(5):565-70. PubMed ID: 14566405
[TBL] [Abstract][Full Text] [Related]
3. D1 dopamine receptor activity of anti-parkinsonian drugs.
Fici GJ; Wu H; VonVoigtlander PF; Sethy VH
Life Sci; 1997; 60(18):1597-603. PubMed ID: 9126882
[TBL] [Abstract][Full Text] [Related]
4. Excitatory and inhibitory action of dopamine on hippocampal neurons in vitro. Involvement of D2 and D1 receptors.
Smiałowski A; Bijak M
Neuroscience; 1987 Oct; 23(1):95-101. PubMed ID: 2960914
[TBL] [Abstract][Full Text] [Related]
5. Effects of dopamine agonists bromocriptine, pergolide, cabergoline, and SKF-38393 on GDNF, NGF, and BDNF synthesis in cultured mouse astrocytes.
Ohta K; Kuno S; Mizuta I; Fujinami A; Matsui H; Ohta M
Life Sci; 2003 Jun; 73(5):617-26. PubMed ID: 12770616
[TBL] [Abstract][Full Text] [Related]
6. Regulation of tyrosine hydroxylase and aromatic L-amino acid decarboxylase by dopaminergic drugs.
Cho S; Neff NH; Hadjiconstantinou M
Eur J Pharmacol; 1997 Apr; 323(2-3):149-57. PubMed ID: 9128833
[TBL] [Abstract][Full Text] [Related]
7. Behavioural role of dopamine D1 receptors in the reserpine-treated mouse.
Starr BS; Starr MS; Kilpatrick IC
Neuroscience; 1987 Jul; 22(1):179-88. PubMed ID: 2957609
[TBL] [Abstract][Full Text] [Related]
8. Catalepsy-associated behavior induced by dopamine D1 receptor antagonists and partial dopamine D1 receptor agonists in squirrel monkeys.
Rosenzweig-Lipson S; Bergman J
Eur J Pharmacol; 1994 Aug; 260(2-3):237-41. PubMed ID: 7988649
[TBL] [Abstract][Full Text] [Related]
9. Decreased striatal dopamine efflux after intrastriatal application of benzazepine-class D1 agonists is not mediated via dopamine receptors.
Zackheim JA; Abercrombie ED
Brain Res Bull; 2001 Apr; 54(6):603-7. PubMed ID: 11403986
[TBL] [Abstract][Full Text] [Related]
10. Activation of D1 and D2 dopamine receptors increases the activity of the somatostatin receptor-effector system in the rat frontoparietal cortex.
Izquierdo-Claros RM; del Boyano-Adánez M; Arilla-Ferreiro E
J Neurosci Res; 2000 Oct; 62(1):91-8. PubMed ID: 11002291
[TBL] [Abstract][Full Text] [Related]
11. Neurochemical evidence of dopamine release by lateral olivocochlear efferents and its presynaptic modulation in guinea-pig cochlea.
Gáborján A; Lendvai B; Vizi ES
Neuroscience; 1999 Apr; 90(1):131-8. PubMed ID: 10188940
[TBL] [Abstract][Full Text] [Related]
12. Behavioural effects of 7-OH-DPAT are solely due to stimulation of dopamine D2 receptors in the shell of the nucleus accumbens; turning behaviour.
Koshikawa N; Kitamura M; Kobayashi M; Cools AR
Eur J Pharmacol; 1996 Jul; 308(3):235-41. PubMed ID: 8858293
[TBL] [Abstract][Full Text] [Related]
13. Activation of D1, but not D2 receptors potentiates dizocilpine-mediated disruption of prepulse inhibition of the startle.
Bortolato M; Aru GN; Fà M; Frau R; Orrù M; Salis P; Casti A; Luckey GC; Mereu G; Gessa GL
Neuropsychopharmacology; 2005 Mar; 30(3):561-74. PubMed ID: 15328529
[TBL] [Abstract][Full Text] [Related]
14. Polydipsia and dopamine: behavioral effects of dopamine D1 and D2 receptor agonists and antagonists.
Mittleman G; Rosner AL; Schaub CL
J Pharmacol Exp Ther; 1994 Nov; 271(2):638-50. PubMed ID: 7965779
[TBL] [Abstract][Full Text] [Related]
15. Evidence for the sensitivity of operant timing behaviour to stimulation of D1 dopamine receptors.
Cheung TH; Bezzina G; Hampson CL; Body S; Fone KC; Bradshaw CM; Szabadi E
Psychopharmacology (Berl); 2007 Dec; 195(2):213-22. PubMed ID: 17668188
[TBL] [Abstract][Full Text] [Related]
16. The dopamine agonists lisuride and piribedil protect against behavioural and histological changes following 4-vessel occlusion in the rat.
Caldwell MA; Reymann JM; Bentue-Ferrer D; Allain H; Leonard BE
Neuropsychobiology; 1996; 34(3):117-24. PubMed ID: 8916068
[TBL] [Abstract][Full Text] [Related]
17. Drug discrimination in methamphetamine-trained monkeys: agonist and antagonist effects of dopaminergic drugs.
Tidey JW; Bergman J
J Pharmacol Exp Ther; 1998 Jun; 285(3):1163-74. PubMed ID: 9618419
[TBL] [Abstract][Full Text] [Related]
18. Dopamine receptor affinities in vitro and stereotypic activities in vivo of cabergoline in rats.
Miyagi M; Itoh F; Taya F; Arai N; Isaji M; Kojima M; Ujiie A
Biol Pharm Bull; 1996 Sep; 19(9):1210-3. PubMed ID: 8889042
[TBL] [Abstract][Full Text] [Related]
19. Dopaminergic control of angiotensin II-induced vasopressin secretion in vitro.
Rossi NF
Am J Physiol; 1998 Oct; 275(4):E687-93. PubMed ID: 9755089
[TBL] [Abstract][Full Text] [Related]
20. Naltrexone, dopamine receptor agonists and antagonists, and food intake in rats: 1. Food deprivation.
Hobbs DJ; Koch JE; Bodnar RJ
Pharmacol Biochem Behav; 1994 Sep; 49(1):197-204. PubMed ID: 7816874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
